Docetaxel Induction Therapy for Head and Neck Cancer
Author Information
Author(s): Posner M R, Lefebvre J L
Primary Institution: Dana-Farber Cancer Institute
Hypothesis
What is the efficacy of docetaxel induction therapy in treating locally advanced squamous cell carcinoma of the head and neck?
Conclusion
Docetaxel induction therapy shows promising response rates and tolerability in patients with locally advanced squamous cell carcinoma of the head and neck.
Supporting Evidence
- Docetaxel has shown significant single-agent activity in recurrent SCCHN.
- Combination therapies with docetaxel have resulted in high overall response rates.
- Phase II studies indicate that docetaxel can improve survival rates in patients with advanced disease.
Takeaway
This study looks at a medicine called docetaxel that helps treat a type of throat cancer, showing it can work well for many patients.
Methodology
The study involved phase II trials assessing the efficacy and safety of docetaxel combined with cisplatin and/or 5-FU in patients with locally advanced SCCHN.
Limitations
The studies included heterogeneous patient populations and varied chemotherapy regimens, which may affect the generalizability of the results.
Participant Demographics
Patients included were primarily men with locally advanced squamous cell carcinoma of the head and neck.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website